

Supplementary Table 1. Sequences of HLA-DR-restricted CD20-derived peptides


Peptide Sequence	Number of amino-acids
huMHC II_Mix 1	
²² AMQSGPKPLFRRMSSLVGPT ⁴¹	20
²⁵ SGPKPLFRRMSSLVGPTQSF ⁴⁴	20
²⁸ KPLFRRMSSLVGPTQSFFMR ⁴⁷	20
huMHC II_Mix 2	
³¹ FRRMSSLVGPTQSFFMRESK ⁵⁰	20
³⁴ MSSLVGPTQSFFMRESKTLG ⁵³	20
³⁷ LVGPTQSFFMRESKTLGAVQ ⁵⁶	20
huMHC II_Mix 3	
⁴⁰ PTQSFFMRESKTLGAVQIMN ⁵⁹	20
⁴³ SFFMRESKTLGAVQIMNG ⁶⁰	18
huMHC II_Mix 4	
⁵⁸ MNGLFHIALGGLLMIPAG ⁷⁵	18
⁹¹ GIMYIISGSLLAATEKNS ¹⁰⁸	18
huMHC II_Mix 5	
¹¹² LVKGMIMNSLSLFAAISGM ¹³¹	20
¹¹⁵ GKMIMNSLSLFAAISGMILS ¹³⁴	20
¹¹⁸ IMNSLSLFAAISGMILSIMD ¹³⁷	20
¹²¹ SLSLFAAISGMILSIMDI ¹³⁸	18
huMHC II_Mix 6	
¹³³ LSIMDILNIKISHFLKMESL ¹⁵²	20
¹³⁶ MDILNIKISHFLKMESLNFI ¹⁵⁵	20
¹³⁹ LNKISHFLKMESLNFIRAH ¹⁵⁸	20
huMHC II_Mix 7	
¹⁴² KISHFLKMESLNFIRAHTPY ¹⁶¹	20
¹⁴⁵ HFLKMESLNFIRAHTPYINI ¹⁶⁴	20
huMHC II_Mix 8	
¹⁴⁸ KMESLNFIRAHTPYINIYNC ¹⁶⁷	20
¹⁵¹ SLNFIRAHTPYINIYNCEPA ¹⁷⁰	20
huMHC II_Mix 9	
¹⁷⁵ KNSPSTQYCYSIQSLFLG ¹⁹²	18
²¹⁴ NEWKRTCSRPKSNIV ²²⁸	15

Supplementary Table 2. IFN- γ responses to CD20-derived human MHC-restricted peptides in cells from healthy donors (PBMCs, $n=26$; splenocytes, $n=7$) and FL patients (PBMCs) ($n=9$)


Samples	Pool 22-43* (SFU/10 ⁵ cells)	Pool 58-121* (SFU/10 ⁵ cells)	Pool 133-151* (SFU/10 ⁵ cells)
PBMC HD1	0	0	6
PBMC HD2	0	0	0
PBMC HD3	0	0	0
PBMC HD4	0	53	4
PBMC HD5	3	53	11
PBMC HD6	3	28	43
PBMC HD7	7	7	13
PBMC HD8	131	56	93
PBMC HD9	0	0	0
PBMC HD10	0	23	6
PBMC HD11	6	85	32
PBMC HD12	309	352	309
PBMC HD13	397	346	361
PBMC HD14	147	109	126
PBMC HD15	229	223	255
PBMC HD16	0	0	0
PBMC HD17	0	0	0
PBMC HD18	0	0	0
PBMC HD19	0	0	0
PBMC HD20	0	2	0
PBMC HD21	3	5	49
PBMC HD22	129	67	230
PBMC HD23	2	5	2
PBMC HD24	0	37	230
PBMC HD25	0	0	131
PBMC HD26	0	0	0
Splenocytes 1	0	212	60
Splenocytes 2	0	9	22
Splenocytes 3	0	7	22
Splenocytes 4	0	0	0
Splenocytes 5	1	16	60
Splenocytes 6	0	71	147
Splenocytes 7	53	0	120

PBMC FL1	18	103	581
PBMC FL2	4	2	11
PBMC FL3	20	12	19
PBMC FL4	0	0	0
PBMC FL5	0	12	0
PBMC FL6	4	44	4
PBMC FL7	0	2	0
PBMC FL8	0	0	0
PBMC FL9	211	16	302


*IFN- γ production in response to human CD20-derived peptide mixture was analyzed by ELISPOT assays as described in the Materials and Methods section. Numbers represent the mean value of triplicates. The positive threshold was set at ≥ 10 spot forming units (SFU) per 10^5 cells as previously described [30]. HD: healthy donors.



Supplementary Figure 1. Frequency of non-responders or responders to one or several pools of MHC II-restricted CD20-derived peptides among healthy individuals or FL patients. Pie charts indicate the percentages of IFN- γ responses by PBMC from healthy donors (PBMC HD, $n=26$) **(a)**, by splenocytes from donors (splenocytes HD, $n=7$) **(b)** or by PBMCs from follicular lymphoma patients (PBMC FL, $n=9$) **(c)** to one (in green), two (in orange), or three (in red) pools of CD20-derived peptides. The percentages of non-responders are indicated in blue.



Supplementary Figure 2. Comparison of IFN- γ responses to the different pools of MHC II-restricted CD20-derived peptides (Pool 22-43, Pool 58-121, Pool 133-151) in PBMCs from healthy donors (PBMC HD, $n=26$, black bars) or from follicular lymphoma patients (PBMC FL, $n=9$, grey bars), and in splenocytes from healthy individuals (splenocytes HD, $n=7$, white bars). IFN- γ production was measured by ELISPOT assays as described in the materials and methods section. Results were expressed as mean value of spot-forming units (SFU) per 10^5 cells. Nonparametric unpaired Mann-Whitney tests were used for statistical analysis. ns: not significant.



Supplementary Figure 3. Representative images of ELISPOT wells depicting IFN- γ responses by PBMCs from one FL patient (FL9) **(a)** and one HD (HD5) **(b)** and their blockade by an anti-HLA-DR, -DP, -DQ antibody. Numbers below images indicate the number of SFU/10⁵ cells obtained in the corresponding well.

¹ NS: non-stimulated cells.